MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ALKEM LABORATORIES - SANOFI INDIA
ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results
Current Valuations
| ALKEM LABORATORIES | SANOFI INDIA | ALKEM LABORATORIES/ SANOFI INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | - | 39.1 | - | View Chart |
| P/BV | x | 6.7 | 6.9 | 97.8% | View Chart |
| Dividend Yield | % | 0.6 | 1.3 | 50.8% |
Financials
 ALKEM LABORATORIES  SANOFI INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALKEM LABORATORIES Mar-16 |
SANOFI INDIA Dec-18 |
ALKEM LABORATORIES/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,589 | 6,840 | 23.2% | |
| Low | Rs | 1,232 | 4,630 | 26.6% | |
| Sales per share (Unadj.) | Rs | 417.5 | 1,203.1 | 34.7% | |
| Earnings per share (Unadj.) | Rs | 56.3 | 165.3 | 34.1% | |
| Cash flow per share (Unadj.) | Rs | 64.7 | 209.9 | 30.8% | |
| Dividends per share (Unadj.) | Rs | 12.70 | 84.00 | 15.1% | |
| Dividend yield (eoy) | % | 0.9 | 1.5 | 61.5% | |
| Book value per share (Unadj.) | Rs | 292.9 | 963.6 | 30.4% | |
| Shares outstanding (eoy) | m | 119.57 | 23.03 | 519.2% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 4.8 | 70.9% | |
| Avg P/E ratio | x | 25.1 | 34.7 | 72.2% | |
| P/CF ratio (eoy) | x | 21.8 | 27.3 | 79.8% | |
| Price / Book Value ratio | x | 4.8 | 6.0 | 80.9% | |
| Dividend payout | % | 22.6 | 50.8 | 44.4% | |
| Avg Mkt Cap | Rs m | 168,653 | 132,078 | 127.7% | |
| No. of employees | `000 | NA | 3.3 | 0.0% | |
| Total wages/salary | Rs m | 9,171 | 4,068 | 225.4% | |
| Avg. sales/employee | Rs Th | NM | 8,393.8 | - | |
| Avg. wages/employee | Rs Th | NM | 1,232.4 | - | |
| Avg. net profit/employee | Rs Th | NM | 1,153.0 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,915 | 27,708 | 180.1% | |
| Other income | Rs m | 1,645 | 897 | 183.4% | |
| Total revenues | Rs m | 51,561 | 28,605 | 180.2% | |
| Gross profit | Rs m | 8,482 | 6,235 | 136.0% | |
| Depreciation | Rs m | 1,006 | 1,027 | 97.9% | |
| Interest | Rs m | 671 | 7 | 9,580.0% | |
| Profit before tax | Rs m | 8,451 | 6,098 | 138.6% | |
| Minority Interest | Rs m | -114 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,606 | 2,292 | 70.1% | |
| Profit after tax | Rs m | 6,731 | 3,806 | 176.9% | |
| Gross profit margin | % | 17.0 | 22.5 | 75.5% | |
| Effective tax rate | % | 19.0 | 37.6 | 50.6% | |
| Net profit margin | % | 13.5 | 13.7 | 98.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 27,062 | 15,922 | 170.0% | |
| Current liabilities | Rs m | 15,324 | 6,235 | 245.8% | |
| Net working cap to sales | % | 23.5 | 35.0 | 67.3% | |
| Current ratio | x | 1.8 | 2.6 | 69.2% | |
| Inventory Days | Days | 67 | 64 | 104.5% | |
| Debtors Days | Days | 41 | 21 | 197.8% | |
| Net fixed assets | Rs m | 12,610 | 7,539 | 167.3% | |
| Share capital | Rs m | 239 | 230 | 104.0% | |
| "Free" reserves | Rs m | 34,490 | 21,962 | 157.0% | |
| Net worth | Rs m | 35,027 | 22,192 | 157.8% | |
| Long term debt | Rs m | 1,212 | 0 | - | |
| Total assets | Rs m | 54,387 | 29,839 | 182.3% | |
| Interest coverage | x | 13.6 | 872.1 | 1.6% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.9 | 0.9 | 98.8% | |
| Return on assets | % | 13.6 | 12.8 | 106.5% | |
| Return on equity | % | 19.2 | 17.2 | 112.1% | |
| Return on capital | % | 24.9 | 27.5 | 90.4% | |
| Exports to sales | % | 12.9 | 0 | - | |
| Imports to sales | % | 3.1 | 0 | - | |
| Exports (fob) | Rs m | 6,461 | NA | - | |
| Imports (cif) | Rs m | 1,540 | NA | - | |
| Fx inflow | Rs m | 6,563 | 7,587 | 86.5% | |
| Fx outflow | Rs m | 3,012 | 7,145 | 42.2% | |
| Net fx | Rs m | 3,552 | 442 | 803.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,259 | 3,739 | 194.1% | |
| From Investments | Rs m | 1,864 | -731 | -255.0% | |
| From Financial Activity | Rs m | -9,273 | -1,972 | 470.2% | |
| Net Cashflow | Rs m | -150 | 1,036 | -14.5% | |
Share Holding
| Indian Promoters | % | 66.9 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 60.4 | - | |
| Indian inst/Mut Fund | % | 33.1 | 14.4 | 229.9% | |
| FIIs | % | 0.0 | 14.6 | - | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 0.0 | 10.5 | - | |
| Shareholders | 68,381 | 15,184 | 450.3% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALKEM LABORATORIES With: TTK HEALTHCARE ALEMBIC LTD WYETH LTD ELDER PHARMA SUVEN LIFESCIENCES
Compare ALKEM LABORATORIES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.
Related Views on News
SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)
Jul 31, 2019 | Updated on Jul 31, 2019For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)
May 8, 2019 | Updated on May 8, 2019For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)
Apr 16, 2019 | Updated on Apr 16, 2019Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.
SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)
Mar 5, 2019 | Updated on Mar 5, 2019For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsMost Popular
Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)
Nov 1, 2019After PI Industries, Hawkins has put up a stellar show so far.
Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)
Oct 30, 2019Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
What to Buy at Sensex 40,000(The 5 Minute Wrapup)
Nov 4, 2019Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?
The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)
Nov 5, 2019Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.
MoreALKEM LABORATORIES SHARE PRICE
Nov 11, 2019 (Close)
TRACK ALKEM LABORATORIES
- Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALKEM LABORATORIES
ALKEM LABORATORIES - SUVEN LIFESCIENCES COMPARISON
COMPARE ALKEM LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.